Q-omics provides the consensus-scored PANK4 profile across patient tissues and cancer cell-line models. PANK4 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, PANK4 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, PANK4 protein abundance shows 20,020 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KICH, HNSC, and LSCC as cancer lineages where PANK4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PANK4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PANK4 survival associations across molecular data types. PANK4 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PANK4 RNA expression–survival associations across cancer types. High PANK4 expression shows unfavorable associations in KICH, ACC and LUSC, but favorable associations in KIRC, CHOL and SCLC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for PANK4 RNA expression.
This table summarizes PANK4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PANK4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PANK4 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LIHC, LUSC and BLCA. The HNSC box plot shows higher PANK4 RNA expression in tumor versus normal tissue (log2 FC = +0.465, t-test p < 0.001).
This table shows molecular features associated with PANK4 in patient tissues and cancer cell lines. In patient samples, PANK4 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PANK4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LIVER.
